NasdaqGM:CMRX

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Chimerix, Inc., a development-stage biopharmaceutical company, focuses on accelerating the advancement of various medicines that impact in the lives of patients living with cancer and other serious diseases. More Details


Snowflake Analysis

Flawless balance sheet with limited growth.


Similar Companies

Share Price & News

How has Chimerix's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CMRX's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-0.7%

CMRX

-1.2%

US Biotechs

-1.1%

US Market


1 Year Return

108.3%

CMRX

30.7%

US Biotechs

15.6%

US Market

Return vs Industry: CMRX exceeded the US Biotechs industry which returned 30.7% over the past year.

Return vs Market: CMRX exceeded the US Market which returned 15.6% over the past year.


Shareholder returns

CMRXIndustryMarket
7 Day-0.7%-1.2%-1.1%
30 Day5.7%1.3%4.2%
90 Day-12.1%-2.5%6.3%
1 Year108.3%108.3%33.0%30.7%18.2%15.6%
3 Year-43.7%-43.7%19.6%13.6%39.6%30.4%
5 Year-93.4%-93.4%8.7%1.0%79.5%59.2%

Price Volatility Vs. Market

How volatile is Chimerix's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Chimerix undervalued compared to its fair value and its price relative to the market?

1.85x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate CMRX's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate CMRX's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: CMRX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: CMRX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CMRX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CMRX is good value based on its PB Ratio (1.8x) compared to the US Biotechs industry average (3.3x).


Next Steps

Future Growth

How is Chimerix forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

7.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CMRX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CMRX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CMRX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CMRX's revenue (24.6% per year) is forecast to grow faster than the US market (10% per year).

High Growth Revenue: CMRX's revenue (24.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CMRX's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Chimerix performed over the past 5 years?

1.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CMRX is currently unprofitable.

Growing Profit Margin: CMRX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CMRX is unprofitable, but has reduced losses over the past 5 years at a rate of 1.6% per year.

Accelerating Growth: Unable to compare CMRX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CMRX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.1%).


Return on Equity

High ROE: CMRX has a negative Return on Equity (-104.87%), as it is currently unprofitable.


Next Steps

Financial Health

How is Chimerix's financial position?


Financial Position Analysis

Short Term Liabilities: CMRX's short term assets ($98.9M) exceed its short term liabilities ($6.2M).

Long Term Liabilities: CMRX's short term assets ($98.9M) exceed its long term liabilities ($2.3M).


Debt to Equity History and Analysis

Debt Level: CMRX is debt free.

Reducing Debt: CMRX has no debt compared to 5 years ago when its debt to equity ratio was 0.4%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CMRX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: CMRX has sufficient cash runway for 1.4 years if free cash flow continues to grow at historical rates of 0.2% each year.


Next Steps

Dividend

What is Chimerix current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CMRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CMRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CMRX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CMRX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CMRX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.6yrs

Average management tenure


CEO

Mike Sherman (54 yo)

1.5yrs

Tenure

US$2,806,926

Compensation

Mr. Michael A. Sherman, also known as Mike, serves as Independent Director at BioSpecifics Technologies Corp. since April 9, 2020. Mr. Sherman has been Chief Executive Officer of Chimerix, Inc. since April ...


CEO Compensation Analysis

Compensation vs Market: Mike's total compensation ($USD2.81M) is above average for companies of similar size in the US market ($USD1.27M).

Compensation vs Earnings: Insufficient data to compare Mike's compensation with company performance.


Leadership Team

NamePositionTenureCompensationOwnership
Michael Sherman
CEO, President & Director1.5yrsUS$2.81m0.17%
$ 298.3k
Michael Andriole
Chief Business Officer1.42yrsUS$1.31m0.24%
$ 414.7k
Michael Alrutz
Senior VP6.08yrsUS$1.17m0.19%
$ 320.8k
David Jakeman
Executive Director of Finance & Accounting and Principal Accounting Officer1.33yrsno data0.032%
$ 55.3k
Roy Ware
Chief Manufacturing & Technology Officer3.75yrsno datano data
Randall Lanier
Chief Science Officer3.75yrsno datano data
Michelle LaSpaluto
Vice President of Strategic Planning & Investor Relations4.75yrsno datano data
Allen Melemed
Chief Medical Officer0.33yrno datano data

2.6yrs

Average Tenure

48.5yo

Average Age

Experienced Management: CMRX's management team is considered experienced (2.6 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Michael Sherman
CEO, President & Director1.5yrsUS$2.81m0.17%
$ 298.3k
Fred Middleton
Independent Director2.58yrsUS$127.69k0.32%
$ 547.1k
Seth Rudnick
Member of Scientific Advisory Boardno datano datano data
Martha Demski
Independent Chairman of the Board2.33yrsUS$148.19k0.060%
$ 102.5k
Douglas Richman
Member of Scientific Advisory Boardno datano datano data
C. Machado
Independent Director6.33yrsUS$132.19k0.016%
$ 27.7k
Michael Boeckh
Member of Clinical Advisory Boardno datano datano data
Earl Kern
Member of Scientific Advisory Boardno datano datano data
Catherine Gilliss
Independent Director6.33yrsUS$105.69k0%
$ 0
Raymund Razonable
Member of Clinical Advisory Boardno datano datano data
Robert Meyer
Independent Director2.58yrsUS$105.69k0.022%
$ 37.4k
Edward Greissing
Independent Director2.58yrsUS$100.69k0%
$ 0

2.6yrs

Average Tenure

68yo

Average Age

Experienced Board: CMRX's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: CMRX insiders have sold more shares than they have bought in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Chimerix, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Chimerix, Inc.
  • Ticker: CMRX
  • Exchange: NasdaqGM
  • Founded: 2000
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$172.295m
  • Shares outstanding: 62.20m
  • Website: https://www.chimerix.com

Number of Employees


Location

  • Chimerix, Inc.
  • 2505 Meridian Parkway
  • Suite 100
  • Durham
  • North Carolina
  • 27713
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CMRXNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDApr 2013
CXFDB (Deutsche Boerse AG)YesCommon StockDEEURApr 2013

Biography

Chimerix, Inc., a development-stage biopharmaceutical company, focuses on accelerating the advancement of various medicines that impact in the lives of patients living with cancer and other serious disease ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/27 00:42
End of Day Share Price2020/10/26 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.